Antonio Jiménez-Velasco

3PUBLICATIONS

24CO-AUTHORS

Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers

Featured researcher

Get your video featured.

Publish with JoVE

Featured researcher

Get your video featured.

Publish with JoVE

Publications (3)

Sort by Publication Date:

|Feb 25, 2023

Toxicity of Asciminib in Real Clinical Practice: Analysis of Side Effects and Cross-Toxicity with Tyrosine Kinase Inhibitors.

Lucía Pérez-Lamas, Alejandro Luna, Concepción Boque

|Sep 02, 2022

No Evidence that CD33 rs12459419 Polymorphism Predicts Gemtuzumab Ozogamicin Response in Consolidation Treatment of Acute Myeloid Leukemia Patients: Experience of the PETHEMA Group.

Tamara Castaño-Bonilla, Eva Barragán, Claudia Sargas

|Mar 10, 2017

A BCR-ABL1 cutoff of 1.5% at 3 months, determined by the GeneXpert system, predicts an optimal response in patients with chronic myeloid leukemia.

Valentín García-Gutiérrez, María T Gómez-Casares, José M Puerta

Pageof 1

Frequent Collaborators

1 joint publications

Tamara Castaño-Bonilla

1 joint publications

Alejandro Sanz

1 joint publications

David Martinez-Cuadron

1 joint publications

Rebeca Rodriguez-Veiga

1 joint publications

Blanca Boluda

1 joint publications

Joaquín Martínez-López

1 joint publications

María José Sayas-Lloris

1 joint publications

Rosalía Riaza-Grau

1 joint publications

María José Larrayoz

1 joint publications

Rosa Ayala

Frequent Collaborators

1 joint publications

Tamara Castaño-Bonilla

1 joint publications

Alejandro Sanz

1 joint publications

David Martinez-Cuadron

1 joint publications

Rebeca Rodriguez-Veiga